Paul J. Lytle
2013
In 2013, Paul J. Lytle earned a total compensation of $790.8K as Chief Financial Officer at Peregrine Pharmaceuticals, a 19% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $158,833 |
|---|---|
| Option Awards | $257,880 |
| Salary | $338,593 |
| Other | $35,448 |
| Total | $790,754 |
Lytle received $338.6K in salary, accounting for 43% of the total pay in 2013.
Lytle also received $158.8K in non-equity incentive plan, $257.9K in option awards and $35.4K in other compensation.
Rankings
In 2013, Paul J. Lytle's compensation ranked 7,623rd out of 12,286 executives tracked by ExecPay. In other words, Lytle earned more than 38.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,623 out of 12,286 | 38th |
Division Manufacturing | 2,752 out of 4,612 | 40th |
Major group Chemicals And Allied Products | 856 out of 1,466 | 42nd |
Industry group Drugs | 644 out of 1,160 | 45th |
Industry Pharmaceutical Preparations | 506 out of 890 | 43rd |
Source: SEC filing on August 28, 2014.
Lytle's colleagues
We found five more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2013.
2013
Steven King
Peregrine Pharmaceuticals
Chief Executive Officer
2013
Jeffrey Masten
Peregrine Pharmaceuticals
Former Vice President, Quality
2013
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
2013
Shelley Fussey
Peregrine Pharmaceuticals
Vice President, Intellectual Property
2013
Joseph Shan
Peregrine Pharmaceuticals